As a result, the company’s growth story is attracting more positive coverage from analysts. The most recent to join the fray is Troy Cheng of OCBC Group Research, who initiated coverage on this counter with a “buy” call and a fair value of 76 cents. “Q&M’s strategic direction in 2026 marks a decisive shift from being a Singapore‑focused clinic operator to building a diversified Asia Pacific dental platform,” says Cheng.
Following the pandemic boost, Q&M Dental Group’s earnings have normalised, which made some investors overlook this stock in the last couple of years. But as investors start to forget about the stock, CEO Dr Ng Chin Siau has been laying the groundwork for ambitious growth plans.
Instead of being contented with just organic growth here in Singapore, the company, armed with $130 million raised from a medium-term note (MTN), is in the midst of a multi-front acquisition binge in markets including Australia and Thailand. The company is also aiming to grow in China separately via its listed subsidiary, Aoxin Q&M Dental Group.
